Founded in December 2016, Laekna Therapeutics is an emerging innovative biotech company based in Zhangjiang Pharma Valley in Shanghai, China and New Jersey, USA. It focuses on developing ground-breaking innovative therapies to treat cancer and liver diseases.
Laekna Therapeutics is adopting a two-pronged strategy in new product development. The company enriches its pipeline by obtaining the global licenses of novel drug candidates in the clinical stage of development for which safety and anti-cancer efficacy have been assessed. The company has obtained the global licenses of four new medicine candidates from Novartis. Meanwhile, Laekna is also establishing its internal product discovery team with multiple preclinical stage molecules. The most advanced molecules will apply for IND and soon move forward to clinical development stages.
Laekna leadership team members have over 20 years of experience in new medicine discovery and development in both China and the US, with an exceptional track record in R&D, new drug approvals and commercialization. Laekna has built its research and clinical development team by attracting top experts from global and local pharmaceutical or biotech companies. Laekna is committed to taking a science-based, innovation-driven approach to build its clinical R&D pipeline, and develop first-in-class and best-in-class innovative medicines. It has been developing an international platform for new product research and development to benefit patients.
company based in
Valley in Shanghai,
China and New
to treat cancer
and liver diseases
December, Laekna established
June, Acquired global licenses of LAE001
May, Completed Series A financing
May, Acquired global licenses of LAE002 & LAE003
August, Completed Series B financing
February, Acquired global licenses of LAE005
October, Completed series C financing
October, Complete series D financing
Q4 1st NDA to be submitted in China and the US
Q4 First internally discovered asset to start global clinical trial
Q2 GMP commercial production site in Lingang, Shanghai to start operation
Glossary & abbreviations:MCRPC: metastatic castration-resistant prostate cancer IND: investigational new drug MRCT: multi-regional clinical trial PROC: platinum-resistant ovarian cancer TNBC: triple negative breast cancer ActRIIA: activin receptor type IIA HR+/HER2- breast cancer: the most common type of breast cancer with overexpression of HR and without overexpression of HER2
Follow us on Linkedin